Mankind Pharma Ltd
Mankind Pharma Q4 FY26 earnings call: Revenue & Margins
Q4 FY26 earnings call: what management said on revenue, margins and capex.
Guidance rank: #57 of 83 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
The short version
Mankind Pharma expects double-digit top-line growth in FY27, aiming to outperform the IPM (Indian Pharmaceutical Market). FY27 revenue growth is expected to be double-digit and outperform the market, driven by recovery in acute therapies and sustained momentum in chronic and specialty products.
From Mankind Pharma Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Mankind Pharma expects double-digit top-line growth in FY27, aiming to outperform the IPM (Indian Pharmaceutical Market).
- Recovery in acute portfolio after muted FY26 performance, with sustained momentum in chronic therapies (cardiac, diabetes, respiratory).
- Increasing contribution from specialty and differentiated products including GLP-1 therapies.
- International business targeted for high teens to 20% growth driven by expansion in women healthcare, IVF products, and semi-regulated markets (Philippines, Malaysia, Africa).
- Modern trade in the OTC segment expected to sustain high teens growth after initial high base growth.
- Focus on expanding doctor prescriptions, increasing gynecologist coverage from 32,000 to 37,000, with 90% IVF center coverage.
2 more points from Mankind Pharma Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Mankind Pharma Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Mankind Pharma approved an investment of up to INR 500 crores in its subsidiary, Mankind Medicare.
- This investment is primarily for setting up a best-in-class biotech facility in Vadodara.
- Capex spend in FY '26 was INR 737 crores, around 5.2% of total revenue, at the higher end of guidance.
- Capex guidance for FY '27 is expected to be 6% to 7% of FY '27 revenue, driven by enhanced R&D focus and specialized product development.
2 more points from Mankind Pharma Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Mankind Pharma Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what Mankind Pharma Ltd said on order book & pipeline — free account, 30 seconds.
Mankind Pharma Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹4.3K Cr, net profit ₹716 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Mankind Pharma Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Balaxi Pharmaceuticals Ltd (Q4 FY26)
Q4 FY26 consolidated revenue: ₹70.71 crore, down 7.3% YoY from ₹76.27 crore in Q4 FY25 (Page 22). Key investor presentation takeaways from Balaxi Pharma's Q4 FY
- Accretion Pharmaceuticals Ltd (Q4 FY26)
45.89 crore, up 18.24% YoY (Page 28). Key investor presentation takeaways from Accretion Pharmaceuticals Ltd's Q4 FY26 investor presentation — and how it ranks
- Gujarat Themis Biosyn Ltd (Q4 FY26)
. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q4 FY26 investor presentation — and how it ranks against sector peers.
- Aptus Pharma Ltd (Q4 FY26)
The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Mankind Pharma Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Mankind Pharma Ltd Q4 FY26 results?
Mankind Pharma expects double-digit top-line growth in FY27, aiming to outperform the IPM (Indian Pharmaceutical Market). FY27 revenue growth is expected to be double-digit and outperform the market, driven by recovery in acute therapies and sustained momentum in chronic and specialty products.
What is Mankind Pharma Ltd share price analysis?
Mankind Pharma Ltd currently shows a neutral. The stock trades at a P/E of 47.0 with a market cap of ₹100,160 Cr. Investors should review the full earnings analysis for detailed insights.
Is Mankind Pharma Ltd planning capital expenditure?
Mankind Pharma approved an investment of up to INR 500 crores in its subsidiary, Mankind Medicare.
Keep Mankind Pharma Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.